Acquired idiopathic inflammatory myopathy
MONDO:0020122An umbrella term for diseases which have chronic muscle inflammation and weakness of unknown etiology. The types of idiopathic inflammatory myopathy are further defined by either clinicopathologic criteria or by the presence of certain autoantibodies.
Also known as: IIm, IMM, idiopathic inflammatory myopathies, idiopathic inflammatory myositis, idiopathic inflammatory myopathy, familial
160 clinical trials for this condition and its sub-types, 67 tagged with Acquired idiopathic inflammatory myopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Acquired idiopathic inflammatory myopathy
-
Polymyositis 36 trials · 100 incl. sub-types
2 sub-types
- Dermatomyositis 81 trials · 100 incl. sub-types Sub-types →
- Juvenile polymyositis 3 trials
-
Juvenile idiopathic inflammatory myopathy 2 trials · 42 incl. sub-types
3 sub-types
- Juvenile dermatomyositis 41 trials
- Juvenile polymyositis 3 trials
- Juvenile overlap myositis 0 trials
-
Antisynthetase syndrome 21 trials
-
Immune-mediated necrotizing myopathy 17 trials
-
Overlap myositis 2 trials
-
Eosinophilic fasciitis 1 trial
-
Focal myositis 0 trials
-
Idiopathic eosinophilic myositis 0 trials
Most studied deeper sub-types
-
Can an oral drug calm inflamed muscles in myositis?
Disease control Stopped earlyResearchers are testing an experimental oral drug called enpatoran in adults with dermatomyositis and polymyositis, two rare muscle-weakening diseases. Participants receive enpatoran or a placebo twice daily for up to 24 weeks while continuing their standard care. The trial measu…
Phase 2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can an extra shot boost COVID protection in autoimmune patients?
Disease control Stopped earlyThis study tests whether an additional dose of a COVID-19 vaccine can improve immune protection in adults and children with autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis, and others who are taking immunosuppressive medications. Participants who had a we…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Hizentra shows promise for rare muscle and skin disease
Disease control Stopped earlyThis study tested a medicine called Hizentra (IgPro20) in 134 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if weekly shots under the skin could improve symptoms better than a placebo. The study was stopped early, but res…
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Lung disease drug tested in rare muscle condition – trial cut short
Disease control Stopped earlyThis study tested the drug nintedanib (Ofev) in 11 people with myositis-related interstitial lung disease, a condition where lung scarring occurs alongside muscle inflammation. The goal was to see if the drug is safe and tolerable when added to standard immune-suppressing treatme…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 26, 2026 13:17 UTC
-
New PET tracer aims to light up inflammation in joint and muscle diseases
Diagnosis Stopped earlyThis early-phase study tested a new radioactive imaging drug called 11C-MC1 to see if it can help detect inflammation in people with rheumatoid arthritis or idiopathic inflammatory myopathy, as well as in healthy volunteers. Participants received PET/CT scans after an injection o…
Phase 1 • Sponsor: National Institute of Mental Health (NIMH) • Aim: Diagnosis
Last updated Jun 26, 2026 18:25 UTC